203 related articles for article (PubMed ID: 10857993)
21. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
22. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species.
Lin HL; Liu TY; Chau GY; Lui WY; Chi CW
Cancer; 2000 Sep; 89(5):983-94. PubMed ID: 10964328
[TBL] [Abstract][Full Text] [Related]
23. Antagonistic effect of the combination gemcitabine/topotecan in ovarian cancer cells.
Distefano M; Ferlini C; De Vincenzo R; Gaggini C; Mancuso S; Scambia G
Oncol Res; 2000; 12(9-10):355-9. PubMed ID: 11697814
[TBL] [Abstract][Full Text] [Related]
24. Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.
Kim MK; James J; Annunziata CM
BMC Cancer; 2015 Mar; 15():196. PubMed ID: 25884494
[TBL] [Abstract][Full Text] [Related]
25. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Ciardiello F; Caputo R; Pomatico G; De Laurentiis M; De Placido S; Bianco AR; Tortora G
Int J Cancer; 2000 Mar; 85(5):710-5. PubMed ID: 10699953
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines.
Riccardi A; Servidei T; Tornesello A; Puggioni P; Mastrangelo S; Rumi C; Riccardi R
Eur J Cancer; 1995; 31A(4):494-9. PubMed ID: 7576952
[TBL] [Abstract][Full Text] [Related]
27. p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
Montariello D; Troiano A; Malanga M; Calabrò V; Quesada P
Biochem Pharmacol; 2013 Apr; 85(7):999-1006. PubMed ID: 23376119
[TBL] [Abstract][Full Text] [Related]
28. Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
Devy J; Wargnier R; Pluot M; Nabiev I; Sukhanova A
Anticancer Res; 2004; 24(3a):1745-51. PubMed ID: 15274350
[TBL] [Abstract][Full Text] [Related]
29. Pifithrin-α enhancing anticancer effect of topotecan on p53-expressing cancer cells.
Guo J; Tang Q; Wang Q; Sun W; Pu Z; Wang J; Bao Y
Eur J Pharm Sci; 2019 Feb; 128():61-72. PubMed ID: 30472223
[TBL] [Abstract][Full Text] [Related]
30. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
Perez-Soler R; Glisson BS; Lee JS; Fossella FV; Murphy WK; Shin DM; Hong WK
J Clin Oncol; 1996 Oct; 14(10):2785-90. PubMed ID: 8874340
[TBL] [Abstract][Full Text] [Related]
31. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
[TBL] [Abstract][Full Text] [Related]
32. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma.
Tsui JY; Dalgard C; Van Quill KR; Lee L; Grossniklaus HE; Edelhauser HF; O'Brien JM
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):490-6. PubMed ID: 18234990
[TBL] [Abstract][Full Text] [Related]
33. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan.
Wildner O; Blaese RM; Morris JC
Hum Gene Ther; 1999 Nov; 10(16):2679-87. PubMed ID: 10566896
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
[TBL] [Abstract][Full Text] [Related]
35. The current status of camptothecin analogues as antitumor agents.
Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
[TBL] [Abstract][Full Text] [Related]
36. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo.
Mason KA; Kishi K; Hunter N; Buchmiller L; Akimoto T; Komaki R; Milas L
Clin Cancer Res; 1999 Dec; 5(12):4191-8. PubMed ID: 10632360
[TBL] [Abstract][Full Text] [Related]
37. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
[TBL] [Abstract][Full Text] [Related]
38. Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01.
Redkar A; Mixter P; Daoud SS
J Exp Ther Oncol; 2004 Oct; 4(3):213-22. PubMed ID: 15724841
[TBL] [Abstract][Full Text] [Related]
39. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Delaney CA; Wang LZ; Kyle S; White AW; Calvert AH; Curtin NJ; Durkacz BW; Hostomsky Z; Newell DR
Clin Cancer Res; 2000 Jul; 6(7):2860-7. PubMed ID: 10914735
[TBL] [Abstract][Full Text] [Related]
40. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
